课题基金 / 基金详情

Artificial Intelligence-empowered approaches towards the development of combination therapies for HER2+/ER+ breast cancer

Artificial Intelligence-empowered approaches towards the development of combination therapies for HER2+/ER+ breast cancer
人工智能支持的 HER2/ER 乳腺癌联合疗法开发方法
批准号:
472362
负责人:
Hu Pingzhao
金额:
$7.29万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2022
资助国家:
加拿大
项目状态:
已结题
起止时间:
2022-09-01 至 2023-09-01

项目摘要

项目成果

Hu Pingzhao的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Human Epidermal Growth Receptor 2-positive breast cancer (HER2+ BC) represents 15-20% of all breast cancers. There are specific treatments (anti-HER2 therapies) for this type of breast cancer. However, half of the HER2+ BC patients are tested positive
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A deep-learning approach to identify inhibitors of adherent-invasive Escherichia coli in the pathogenesis of inflammatory bowel disease
  • 批准号:
    480198
  • 项目类别:
    Operating Grants
  • 资助金额:
    $60.47万
  • 财政年份:
    2023
  • 负责人:
    Hu Pingzhao
  • 依托单位:
Canada Research Chair - Tier 2
  • 批准号:
    471104
  • 项目类别:
  • 资助金额:
    $43.71万
  • 财政年份:
    2022
  • 负责人:
    Hu Pingzhao
  • 依托单位:
海外基金